STOCK TITAN
  1. Home
  2. News
  3. NUWE

Nuwellis, Inc. - $NUWE STOCK NEWS

Welcome to our dedicated page for Nuwellis news (Ticker: $NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuwellis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuwellis's position in the market.

News
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
Rhea-AI Summary
Nuwellis, Inc. announces that its strategic partner, SeaStar Medical Holding Corporation, has received an Approvable Letter from the FDA for its pediatric Selective Cytopheretic Device (SCD-PED). The SCD-PED will provide a new therapy option for children with acute kidney injury and sepsis. The Approvable Letter indicates that SeaStar Medical's HDE application meets the requirements for an Approval Order, with minor administrative steps remaining. Clinical data showed a 77% reduction in mortality rate and no dialysis dependency at Day 601,2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.3%
Tags
fda approval
-
News
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023
Rhea-AI Summary
Nuwellis, Inc. to release Q3 2023 financial results on November 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.25%
Tags
earnings
-
News
Nuwellis Announces Closing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
Rhea-AI Summary
Nuwellis, Inc. has closed its public offering of 150,000 units, consisting of Series J Convertible Redeemable Preferred Stock and warrants. The purchase price for one unit was $15. The Series J Convertible Preferred Stock has a term of three years and is convertible at the option of the holder. Dividends on the Series J Convertible Preferred Stock will be paid in-kind in additional shares. The gross proceeds from the offering were approximately $2.25 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
offering
News
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
Rhea-AI Summary
Nuwellis, Inc. announces pricing of public offering of 150,000 units
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.91%
Tags
offering
-
News
Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
Rhea-AI Summary
Nuwellis announces FDA approval progress for pediatric kidney therapy device
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.94%
Tags
none
-
News
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase
Rhea-AI Summary
Nuwellis, Inc. to participate in fireside chat at Gilmartin Group Emerging Growth Showcase
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences acquisition
News
Nuwellis, Inc. Announces Second Quarter 2023 Financial Results
Rhea-AI Summary
Nuwellis reports Q2 2023 financial results with revenue of $2.1 million, a 14% increase over the prior quarter. Gross margin rate improves to 55.3%. The company enters a Supply and Collaboration Agreement with DaVita Inc. Cash and cash equivalents are approximately $9 million with no debt.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
earnings
-
News
Nuwellis Announces Plan for CFO Transition
Rhea-AI Summary
Nuwellis, Inc. (NUWE) announces the transition of CFO Lynn Blake and the appointment of Rob Scott as her successor. Ms. Blake will remain in her role through September 1, 2023, and consult with the Company through March 31, 2024. Mr. Scott, a 10-year veteran of Nuwellis, is set to be appointed as CFO at the next Board of Directors meeting. The company expresses gratitude to Ms. Blake for her contributions and excitement for Rob's promotion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
none
-
News
Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023
Rhea-AI Summary
Nuwellis, Inc. will release its second quarter 2023 financial results on August 8, 2023. The company will host a conference call and webcast to discuss the results and provide a general business overview.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
earnings
News
Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.
Rhea-AI Summary
Nuwellis, Inc. has entered into a Supply and Collaboration Agreement with DaVita Inc. to pilot Aquadex ultrafiltration therapy in select U.S. markets. The agreement aims to expand access to ultrafiltration therapy for heart failure patients and reduce healthcare costs. The pilot program is expected to launch by the end of Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
Stock NUWE logo
Nuwellis, Inc.

Nasdaq:NUWE

NUWE Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NUWE Stock Data

3.97M
6.79M
0.06%
3.14%
12.08%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
EDEN PRAIRIE

About NUWE

chf solutions is an early stage company focused on commercializing the aquadex flexflow system. our objective is to improve the quality of life for patients with heart failure and related conditions, such as fluid overload. at chf solutions, we are committed to the relentless pursuit of identifying and developing innovative solutions to address unmet clinical needs with the goal of benefiting patients, medical practitioners, and the broader healthcare community. if you are looking for a career where you can make difference we would like to hear from you. we are looking for highly skilled, highly motivated people who want to be part of a growing company where everything you do will matter. chf solutions is an equal opportunity/affirmative action employer committed to cultural diversity in the workplace.